Amyloid Imaging: Poised for Integration into Medical Practice

Document Type

Article

Abstract

Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer’s disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, 11C-PIB was developed, which was the prototype for many 18F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date.

Publication Date

1-1-2017

Publication Title

Neurotherapeutics

ISSN

19337213

E-ISSN

18787479

Volume

14

Issue

1

First Page

54

Last Page

61

PubMed ID

27571940

Digital Object Identifier (DOI)

10.1007/s13311-016-0474-y

Link to Full Text

Share

COinS